Table 1 Baseline demographics and clinical characteristics

Patient characteristics

 Sex (M/F)

14 (17.7%) / 65 (82.3%)

 Age (y)

69 [26–90]

Tumour type

 HCC

71 (89.8%)

 ICC

4 (5.1%)

 mCRC

4 (5.1%)

Normal liver and tumoral liver volumes

 TL (ml)

198.03 [4.56–2228.42]

 NTLt (ml)

955.67 [13.46–2039.70]

 NTLw (ml)

1562.25 [727.40–2980.48]

 Lobe (left) (ml)

644.35 [209.93–1995.80]

 Lobe (right) (ml)

1478.25 [484.50–2762.90]

 Whole Liver (ml)

1845.09 [819.19–3458.50]

Tumour involvement^a

 Total (%)

18.90 [0.50–95.10]

 Patients with < 5%

14 (17.7%)

 Patients with 5–10%

12 (15.1%)

 Patients with 10–25%

28 (35.4%)

 Patients with 25–50%

14 (17.7%)

 Patients with > 50%

11 (13.9%)

Number of lesions

 Patients with 1 lesion

66 (77.2%)

 Patients with 2 lesions

7 (8.8%)

 Patients with 3 lesions

6 (13.9%)

Diagnostic image modality

 Contrast-enhanced CT

59 (74.7%)

 Contrast-enhanced MRI

20 (25.3%)

Simulation (^99mTc-MAA) and therapy (⁹⁰Y) characteristics

 Treated lobe (left/right)

19 (24.1%) / 60 (75.9%)

 LSF (%)

8.0 [0.6–21.0]

 Waiting period^b (d)

20 [9–47]

 ^99mTc-MAA activity (MBq)

152.0 [60.0–190.0]

 ⁹⁰Y activity (GBq)

2.57 [0.74–5.9]

  HCC (GBq)

2.50 [0.74–5.5]

  ICC (GBq)

3.28 [2.2–4.2]

  mCRC (GBq)

3.90 [1.9–5.9]